Compare SQNS & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | VRCA |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 88.0M |
| IPO Year | 2011 | 2018 |
| Metric | SQNS | VRCA |
|---|---|---|
| Price | $2.90 | $4.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $20.33 | $17.00 |
| AVG Volume (30 Days) | 27.1K | ★ 94.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $49.79 | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $2.38 | $3.28 |
| 52 Week High | $10.93 | $9.82 |
| Indicator | SQNS | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 35.82 |
| Support Level | $2.72 | $4.52 |
| Resistance Level | $3.20 | $5.94 |
| Average True Range (ATR) | 0.13 | 0.40 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 71.90 | 4.92 |
Sequans Communications SA is a fabless semiconductor company specializing in wireless 4G and 5G cellular technologies for the Internet of Things (IoT). Sequans' engineers design and develop, secure, and energy-efficient semiconductor solutions that enable the next generation of AI-connected applications, including smart energy metering, industrial automation, smart mobility and logistics, secure payments, e-health, and smart home solutions. The Company offers a comprehensive portfolio of wireless connectivity solutions, including radio frequency (RF) transceivers, integrated circuits (ICs) for baseband processing, as well as modules, software, & protocol stacks. The Company has one operating segment, which is the design & marketing of semiconductor components for cellular wireless systems.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.